---
figid: PMC9030030__cancers-14-01873-g003
figtitle: 'Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage T-ALL
  Subsets'
organisms:
- Homo sapiens
- Mus musculus
- Candida dubliniensis
pmcid: PMC9030030
filename: cancers-14-01873-g003.jpg
figlink: /pmc/articles/PMC9030030/figure/cancers-14-01873-f003/
number: F3
caption: 'Schematic representation of the possible inhibitory points in the FLT3 signaling
  pathway. Type II FLT3 inhibitors such as sorafenib act in the inactivated FLT3 receptor
  (represented as an FLT3 monomer). Active FLT3 transduces signaling through (1) the
  Ras/Raf/MEK/ERK pathway, which, in turn, can be inhibited by pan- or specific MEK
  inhibitors; (2) the PIK3/Akt/mTOR pathway, which is also inactivated by specific
  mTOR inhibitors; and (3) JAK/STAT signaling, which might also be inhibited by the
  specific JAK1/2 inhibitor ruxolitinib. In addition, venetoclax can block the anti-apoptotic
  signaling effects of Bcl-2. MEK, mTOR, JAK, and Bcl-2 inhibitors can also be used
  in any T-ALL cases showing activation of the target proteins. TMD: transmembrane
  domain; ICD: intracellular domain; TKID-I and II: tyrosine kinase domain I and II;
  Sor: sorafenib; Rux: ruxolitinib; Ven: venetoclax. Created with BioRender.com, accessed
  on 16 February 2022.'
papertitle: 'Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage
  T-ALL Subsets.'
reftext: Eulàlia Genescà, et al. Cancers (Basel). 2022 Apr;14(8):1873.
year: '2022'
doi: 10.3390/cancers14081873
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: immature T-ALL | ETP-ALL | diagnosis | genomics | outcome | treatment
automl_pathway: 0.9416285
figid_alias: PMC9030030__F3
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC9030030__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9030030__cancers-14-01873-g003.html
  '@type': Dataset
  description: 'Schematic representation of the possible inhibitory points in the
    FLT3 signaling pathway. Type II FLT3 inhibitors such as sorafenib act in the inactivated
    FLT3 receptor (represented as an FLT3 monomer). Active FLT3 transduces signaling
    through (1) the Ras/Raf/MEK/ERK pathway, which, in turn, can be inhibited by pan-
    or specific MEK inhibitors; (2) the PIK3/Akt/mTOR pathway, which is also inactivated
    by specific mTOR inhibitors; and (3) JAK/STAT signaling, which might also be inhibited
    by the specific JAK1/2 inhibitor ruxolitinib. In addition, venetoclax can block
    the anti-apoptotic signaling effects of Bcl-2. MEK, mTOR, JAK, and Bcl-2 inhibitors
    can also be used in any T-ALL cases showing activation of the target proteins.
    TMD: transmembrane domain; ICD: intracellular domain; TKID-I and II: tyrosine
    kinase domain I and II; Sor: sorafenib; Rux: ruxolitinib; Ven: venetoclax. Created
    with BioRender.com, accessed on 16 February 2022.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Flt3
  - Stat5a
  - Stat3
  - Cd48
  - Sri
  - Jak1
  - Shc1
  - Akt1
  - Mtor
  - Ubtf
  - Myc
  - Nol3
  - ras
  - Hras
  - Kras
  - Rem1
  - Bad
  - Bcl2
  - Zhx2
  - Mdk
  - Map2k1
  - Map2k2
  - Mapk3
  - Mapk1
  - Nfkb1
  - Creb1
  - FLT3
  - STAT5A
  - STAT5B
  - STAT3
  - SOAT1
  - STAT1
  - STAT2
  - STAT4
  - STAT6
  - CD48
  - JAK1
  - TTN
  - GNPTAB
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - AKT1
  - AKT2
  - AKT3
  - PIK3CG
  - MTOR
  - UBTF
  - MYC
  - KRAS
  - HRAS
  - NRAS
  - BAD
  - BCL2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
---
